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Introduction
Menopause, the end of ovulation and menstrual periods,
naturally occurs for most women at the age of 40–55
years. The process of ending ovulation and menstrua-
tion is gradual, spanning 1 to 2 years. Postmenopausal
bleeding (PMB) is bleeding that occurs 12 or more
months after the last menstrual period and accounts
for 5% of all gynecologic office visits1. Moreover, a re-
ported 25% of gynecologic surgeries involve abnormal
uterine bleeding2.
The response for the postmenopausal individual
will depend on her own specific endometrial sensitiv-
ity, as well as the magnitude of the dose of the hor-
mone supplement. Approximately one in 10 women
will experience some bleeding after the menopause3.
Postmenopausal bleeding should always be taken
seriously and be investigated, no matter how minimal
or nonpersistent. Causes may be nongenital, genital
extrauterine or uterine4. Possible uterine conditions
associated with PMB include endometrial atrophy,
polyps, estrogen therapy, foreign bodies, trauma, infec-
tion, endometrial hyperplasia, and carcinoma (Table)4,5.
Uterine myoma should never be accepted as a cause
of PMB. Endometrial atrophy is the most common endo-
metrial finding in women with PMB, accounting for
60–80% of such bleeding. Women with endometrial
atrophy have usually been menopausal for 10 years.
Hormonal replacement therapy accounts for 15–25%
of PMB. The uterine lining responds to supplemental
hormone stimulation just as it did earlier in the woman’s
ASSESSMENT OF POSTMENOPAUSAL BLEEDING
Chin-Yuan Hsu1,2*, Chih-Ping Chen1,3, Kung-Liahng Wang1,2,4
1Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 2Mackay Medicine, Nursing and 
Management College, 3Yang-Ming University, and 4National Taipei College of Nursing, Taipei, Taiwan.
SUMMARY
Postmenopausal bleeding is bleeding that occurs 12 or more months after the last menstrual period and
accounts for 5% of all gynecologic office visits. While it is not always a symptom of cancer, the exclusion of
endometrial hyperplasia and carcinoma is the key issue in the evaluation of patients with postmenopausal
bleeding. The primary evaluation of postmenopausal women who present with abnormal uterine bleeding
includes a medical history and a pelvic examination. Investigative studies, such as a uterine biopsy, ultrasound,
hysteroscopy or dilation and curettage, may be required. Treatment will depend on the cause determined. The
most important point is that irregular perimenopausal or postmenopausal bleeding should not be ignored or
assumed to be a normal phenomenon. [International Journal of Gerontology 2008; 2(2): 55–59]
Key Words: dilatation and curettage, hysteroscopy, postmenopause, ultrasound, uterine bleeding
*Correspondence to: Dr Chin-Yuan Hsu, Department
of Obstetrics and Gynecology, Mackay Memorial
Hospital, 92, Chung-Shan North Road, Section 2,
Taipei, Taiwan.
E-mail: hsu4426@ms4.hinet.net
Accepted: February 2, 2008
■ REVIEW ARTICLE
© 2008 Elsevier.
Table. Etiology of postmenopausal bleeding
Cause of bleeding %
Endometrial atrophy 60–80
Exogenous estrogens 15–25
Endometrial or cervical polyps 2–12
Endometrial hyperplasia 5–10
Endometrial cancer 10
Miscellaneous (e.g., cervical cancer, 10 
uterine sarcoma, trauma)
reproductive life. Unopposed moderate- or high-dose
estrogen therapy when compared with placebo is asso-
ciated with a significant increase in rates of endometrial
hyperplasia with increasing rates at longer duration of
treatment and follow-up6. Irregular bleeding and non-
adherence to treatment are also significantly more likely
under these unopposed estrogen regimens that increase
bleeding with higher-dose therapy. The addition of oral
progestogens administered either sequentially or con-
tinuously is associated with reduced rates of hyperplasia
and improved adherence to therapy. Irregular bleeding
is less likely under sequential rather than continuous
therapy during the first year of therapy; but there is 
a suggestion that continuous therapy of a long duration
is more protective than sequential therapy in the pre-
vention of endometrial hyperplasia6.
Determining the underlying cause of PMB requires
a thorough evaluation by a gynecologist. Treatment
will obviously depend on the cause of PMB. The pri-
mary evaluation includes the history and a pelvic ex-
amination, as well as a Pap smear if appropriate, to look
for vulvar or vaginal lesions, signs of trauma, and cer-
vical polyps or dysplasia. Cervical dysplasia seldom
causes abnormal uterine bleeding, but it may be asso-
ciated with postcoital bleeding7. Cervical cultures may
be indicated if the patient is at risk for infection or if
symptoms of infection are present. While the majority of
causes of PMB are benign, up to 10% of women with
PMB will be diagnosed with uterine cancer8. Malignancy
must be excluded as a cause of bleeding in postmen-
opausal patients. Postmenopausal bleeding is the most
important presenting symptom of endometrial cancer.
Investigative studies, such as an endometrial biopsy, ul-
trasound, dilatation and curettage (D&C) or hysteroscopy,
may be required.
Diagnostic Tools
Hormonal status, including results of hormone
replacement therapy, has demonstrable effects on the
endometrium and plays a major role in investigation of
the causes of abnormal uterine bleeding. Because 90%
of PMB is associated with a benign condition, the ideal
diagnostic method is noninvasive. Ultrasonography is
typically used in the initial evaluation of PMB and for
the guidance of further diagnostic tests9. Further evalu-
ation for subtle genital tract pathology is recommended
in patients who are at high risk for endometrial cancer
and in patients at low risk who continue bleeding ab-
normally despite medical management10. The patients’
individual risk factors for endometrial cancer may influ-
ence the procedure or combination of procedures to be
chosen. Hypertension, obesity, polycystic ovarian dis-
ease, diabetes, tamoxifen therapy, and colon or breast
cancer are risk factors in addition to age11,12. The risk of
developing endometrial cancer increases with age12.
In women aged 40–49 years, the incidence rate of endo-
metrial cancer is 36.5 cases per 100,000 in the United
States. Endometrial carcinoma is most common in the
postmenopausal age group and is most prevalent in
women over 50 years of age. Thus, the American College
of Obstetricians and Gynecologists recommends endo-
metrial evaluation in women with abnormal uterine
bleeding and aged 35 years and older10.
Noninvasive Diagnostic Procedures
Ultrasound
Differential diagnoses for causes of abnormal vaginal
bleeding in postmenopausal patients can be well eval-
uated with transvaginal ultrasonography. It has greatly
facilitated evaluation of pelvic disease, including leiomy-
oma, endometrial thickening or focal masses. Although
this imaging modality may miss endometrial polyps and
submucous fibroids, it is highly sensitive for the detec-
tion of endometrial cancer (96%) and endometrial ab-
normality (92%)13. Compared with D&C, endometrial
evaluation with transvaginal ultrasonography is about
4% less accurate13,14. However, it may be the most cost-
effective initial test in women at low risk for endometrial
cancer, and these include those who have abnormal
uterine bleeding that does not respond to medical
management9.
The exclusion of endometrial hyperplasia and 
carcinoma is the key issue in the evaluation of patients
with abnormal uterine bleeding. Transvaginal ultra-
sound measurement of endometrial thickness has be-
come a routine procedure and an initial investigation
in patients with abnormal uterine bleeding. The peri-
and postmenopausal endometrial thickness is normally
less than that in the premenopausal patient (Figure 1).
During menopause, the endometrium primarily con-
sists of a thin basalis layer, and the measurement of the
endometrial echo complex represents the apposition
of the two basal layers15. In general, along with endo-
metrial thickening, the sonographic characteristics of
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hyperechogenicity and heterogeneous texture repre-
sent higher risks for cancer than other patterns. An
enlarged uterus, fluid within the cavity, increased blood
flow, and an irregular interface of the endometrium
and myometrium also suggest cancer (Figure 2).
There is debate as to whether a cut-off of 5 or 4 mm
for endometrial thickness should be employed3. Trans-
vaginal ultrasound examination can reliably distinguish
women with PMB who are at low risk of endometrial
pathology (endometrial thickness ≤4 mm) from those
who are at high risk (endometrium ≥5 mm). The 5-mm
cut-off is applicable irrespective of the use of hormone
replacement therapy. It is justified to refrain from
endometrial sampling in women with PMB and an en-
dometrial thickness of ≤4 mm, because the risk of
endometrial cancer in these women is low (0.1–1.0%)16.
However, it is not known whether these women need
follow-up. About 80% of women with PMB and an
endometrium of ≥5 mm have focally growing patho-
logic lesions in the uterine cavity. These should be re-
moved by operative hysteroscopy, because D&C will fail
to diagnose and remove a large proportion of lesions16.
Although transvaginal ultrasonographic measure-
ment of the endometrium is a useful, highly sensitive
and noninvasive procedure, it has limitations. Some
investigators have determined that it has low positive
predictive value for cancer. This is especially true in
women taking hormone therapy and tamoxifen, or
women with recurrent PMB or PMB that occurs long
after the menopause17.
Sonohysterography
A refinement of vaginal probe ultrasound is saline
infusion sonohysterography. A saline solution is injected
into the uterus with a catheter before the vaginal probe
is inserted. The presence of liquid in the uterus helps
make any structural abnormalities more distinct. Its
sensitivity and specificity for endometrial cancer is com-
parable with the high sensitivity and specificity of diag-
nostic hysteroscopy18. Saline infusion sonohysterography
is more accurate than transvaginal ultrasonography 
in diagnosing intracavitary lesions19,20, and is more ac-
curate than hysteroscopy in diagnosing endometrial
hyperplasia21. This test is highly sensitive (95–97%) and
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Figure 1. Coronal ultrasonographic images of the uterus: (A) before the menopause, showing a normal, 10-mm (arrows)
endometrial echo complex; (B) after the menopause, showing a thin, 3-mm (arrows) endometrial echo complex.
Figure 2. Sagittal ultrasonographic image of a 62-year-old
patient shows marked irregular thickening of the endo-
metrium. Pathologic analysis demonstrated endometrial
carcinoma.
also has a specificity of 70–98% for the identification
of endometrial abnormality when combined with 
directed endometrial biopsy22,23. Recent papers support
the high diagnostic accuracy and conclude that saline
infusion sonography is able to replace diagnostic hys-
teroscopy in the evaluation of the uterine cavity24. The
use of gel instead of saline as distension medium and
the introduction of new three-dimensional inversion
rendering techniques enhance the visualization of the
endometrium and may improve the diagnostic accuracy
of saline infusion sonography.
Hysteroscopy
Hysteroscopy is a special test that entails the passing
of a tiny telescope through the cervix, allowing the actual
visualization of the uterine cavity. Fibroids or polyps can
be seen and removed and the suspicious area of tissue
biopsied under direct vision. The accuracy of hysteros-
copy is most useful in the diagnosis of cancer when
compared with other types of endometrial disease. In
a case series of 181 patients, the sensitivity was 96.6%
and the specificity 100% when hysteroscopy was used
in conjunction with endometrial biopsy25. Although effi-
cient in the detection of pathologic intrauterine lesions,
it is only moderately successful in determining physio-




Endometrial biopsy is a simple office procedure which
allows physicians to sample small areas of the uterine
lining, while cervical biopsy allows the cervix to be
sampled. A flexible catheter is introduced into the
uterus, and the endometrial sample is obtained by gen-
tle suction. This procedure is less invasive than D&C.
Many family practice clinicians in the United States
routinely perform endometrial biopsy. It is not known
whether simple endometrial biopsies are as reliable as
D&C in women without focal lesions15. The sensitivity
of endometrial biopsy for the detection of endome-
trial abnormalities has been reported to be as high as
96%26. However, this office-based procedure may miss
up to 18% of focal lesions27 including polyps and
fibroids, because only a small part of the endometri-
um may be sampled at any one time. Although endo-
metrial biopsy has high sensitivity for endometrial
carcinoma, its sensitivity for detecting atypical endome-
trial hyperplasia may be as low as 81%28,29.
D&C
D&C is often necessary for definitive diagnosis.
Postmenopausal women with abnormal uterine bleed-
ing, including those who have been receiving hormone
therapy for more than 12 months, should be offered
D&C for evaluation of the endometrium (96% sensitivity
for the detection of cancer, with a 2–6% false-negative
rate)13. Although D&C has been the gold standard for
diagnosing endometrial cancer30, it is no longer consid-
ered to be therapeutic for abnormal uterine bleeding;
furthermore, it is limited in its ability to access the tubal
cornua of the uterus31.
Conclusion
Bleeding after the menopause is not an uncommon
event. While it is not always a symptom of cancer, any
amount of bleeding, scant or large, needs to be evalu-
ated. The exclusion of endometrial hyperplasia and car-
cinoma is the key issue in the evaluation of patients with
abnormal uterine bleeding. Transvaginal ultrasound
measurement of endometrial thickness has become a
routine procedure and an initial investigation in patients
with abnormal uterine bleeding. Hysteroscopy allows
visualization of the uterine cavity and the opportunity
for targeted biopsy and removal of endometrial polyps.
Outpatient endometrial biopsy, as well as D&C, is consid-
ered to be the gold standard for obtaining endometrial
tissue. In conclusion, postmenopausal women with ab-
normal uterine bleeding, including those who have been
receiving hormone therapy for more than 12 months,
should be offered D&C for evaluation of the endo-
metrium. Women who are poor candidates for general
anesthesia and those who decline D&C may be offered
transvaginal ultrasonography or saline infusion sono-
hysterography with endometrial biopsy. It is important
to use the correct diagnostic tools to assess each patient,
according to individual needs and histories.
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